Epigral Ltd

Epigral Ltd is rated 'Sell' by MarketsMOJO, a rating that was last updated on 26 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 20 April 2026, providing investors with an up-to-date view of the company's performance and outlook.

The Sensex climbed 1.23% on 10 Apr 2026, yet Epigral Ltd outpaced the broader market with a 7.36% gain, touching an intraday high of Rs 1084.75. This 5.06 percentage-point outperformance over its Specialty Chemicals sector peers signals a distinctly stock-specific rally rather than a market-wide lift.

Epigral Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 26 Dec 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 09 April 2026, providing investors with an up-to-date view of the company’s performance and outlook.

The Sensex advanced 4.03% on 8 Apr 2026, yet Epigral Ltd outpaced both the benchmark and its sector with a 7.28% gain, touching an intraday high of Rs 1022.6. This 4.65-percentage-point outperformance signals a distinctly stock-specific rally rather than a broad market lift.

Epigral Ltd, a small-cap player in the Specialty Chemicals sector, has exhibited a notable shift in price momentum and technical indicators, reflecting a complex market stance. Despite a strong intraday gain of 6.01% to close at ₹954.40 on 8 Apr 2026, the stock’s technical parameters reveal a nuanced picture with mixed signals across weekly and monthly timeframes.

The Sensex declined by 2.20% on 1 Apr 2026, while Epigral Ltd surged 7.09%, marking a 4.89-percentage-point outperformance over the benchmark. This sharp intraday gain, reaching a high of Rs 866.2, stands out as a stock-specific event amid a broadly weak market environment.

Epigral Ltd’s share price declined to a fresh 52-week low of Rs.806.2 on 30 March 2026, marking a significant drop amid broader market weakness and sectoral pressures. The stock’s recent performance reflects ongoing challenges in both near-term results and longer-term growth metrics within the specialty chemicals sector.

Epigral Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 26 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 29 March 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Despite a broader market rally, Epigral Ltd has plunged to a fresh 52-week low of Rs 822 on 23 Mar 2026, marking a steep 57.05% decline over the past year and underscoring persistent headwinds unique to the stock.

Epigral Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 26 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 18 March 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.

Epigral Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 26 Dec 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 07 March 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Epigral Ltd, a specialty chemicals company, opened the trading session with a pronounced gap down, reflecting heightened market concerns following a series of negative performance indicators and a downgrade in its mojo grade. The stock’s opening price plunged by 7.93%, marking a fresh 52-week low and continuing a downward trend that has persisted over the past week.

Epigral Ltd, a key player in the Specialty Chemicals sector, has touched a new 52-week low of Rs.822.05 today, marking a significant decline amid a sustained downward trend. The stock’s performance continues to lag behind its sector and broader market indices, reflecting ongoing pressures on its financial metrics and market valuation.

Epigral Ltd, a player in the Specialty Chemicals sector, recorded a fresh 52-week low of Rs.901.6 today, marking a significant milestone in its ongoing price decline. The stock has underperformed its sector and broader market indices, reflecting a challenging period for the company’s equity performance.

Epigral Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 26 December 2025. However, the analysis and financial metrics presented here reflect the stock's current position as of 24 February 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Epigral Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 26 December 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 12 February 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.